

FOI 3167

9<sup>th</sup> July 2025

---

**FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST**

---

**A. How many patients have been treated with the following drugs in the past 4 months:**

**Atogepant (Aquipta) –**

**Response:**

No data held, issued in primary care

**Erenumab (Aimovig)**

**Response:**

No data held, issued in primary care

**Eptinezumab (Vyepiti) Any disease**

**Response:**

4

**Fremanezumab (Ajovy)**

**Response:**

No data held, issued in primary care

**Galcanezumab (Emgality)**

**Response:**

No data held, issued in primary care

**Rimegepant (Vydura)**

**Response:**

No data held, issued in primary care

**Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY**

**Response:**

190

**How many patients have you treated in the last 4 months for acute migraine with Rimegepant (Vydura)**

**Response:**

No data held, issued in primary care

**Does the trust actively initiate a treatment pause (usually at 12 months) of anti-CGRP (calcitonin gene-related peptide inhibitors) migraine treatment with the aim to re-start treatment if the patient continues to fit the criteria (Yes/No)?**

**Response:**

Yes our service stops treatment of anti CGRP migraine treatment after 12 months of treatment. The patient then has 4 months off the medication and is reassessed in clinic thereafter to determine if needs treatment restarted.

Email: [Foi.Team@Southerntrust.hscni.net](mailto:Foi.Team@Southerntrust.hscni.net)